chr16-89510491-G-A
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 2P and 2B. PM2BP4_Moderate
The NM_003119.4(SPG7):c.185G>A(p.Ser62Asn) variant causes a missense, splice region change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000778 in 1,451,550 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 18/23 in silico tools predict a benign outcome for this variant. 3/3 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Uncertain significance (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. S62R) has been classified as Uncertain significance.
Frequency
Consequence
NM_003119.4 missense, splice_region
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 0 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
SPG7 | NM_003119.4 | c.185G>A | p.Ser62Asn | missense_variant, splice_region_variant | 2/17 | ENST00000645818.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
SPG7 | ENST00000645818.2 | c.185G>A | p.Ser62Asn | missense_variant, splice_region_variant | 2/17 | NM_003119.4 | P2 |
Frequencies
GnomAD3 genomes AF: 0.0000205 AC: 3AN: 146048Hom.: 0 Cov.: 31
GnomAD3 exomes AF: 0.0000128 AC: 3AN: 234826Hom.: 0 AF XY: 0.0000157 AC XY: 2AN XY: 127280
GnomAD4 exome AF: 0.0000843 AC: 110AN: 1305502Hom.: 0 Cov.: 27 AF XY: 0.0000778 AC XY: 51AN XY: 655182
GnomAD4 genome AF: 0.0000205 AC: 3AN: 146048Hom.: 0 Cov.: 31 AF XY: 0.0000141 AC XY: 1AN XY: 70698
ClinVar
Submissions by phenotype
not provided Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Jan 04, 2017 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Aug 19, 2021 | - - |
Hereditary spastic paraplegia 7 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Aug 25, 2016 | In summary, this variant is a rare missense change that is not predicted to affect protein function. There is no indication that it causes disease, but the available evidence is currently insufficient to prove that conclusively. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function output the following: (SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0"). The asparagine amino acid residue is also found in multiple mammalian species, suggesting that this missense change does not adversely affect protein function. These predictions have not been confirmed by published functional studies. This variant is present in population databases at a very low frequency  (rs143294686, ExAC <0.01%) but has not been reported in the literature in individuals with a SPG7-related disease. This sequence change replaces serine with asparagine at codon 62 of the SPG7 protein (p.Ser62Asn). The serine residue is weakly conserved and there is a small physicochemical difference between serine and asparagine. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at